VERU INC. - COMMON STO

Veru Participates in a Virtual Investor KOL Connect Segment

08 May 2025 08:25:00 By Nasdaq GlobeNewswire

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

08 May 2025 05:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

01 May 2025 07:30:00 By Nasdaq GlobeNewswire

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

16 Apr 2025 07:30:00 By Nasdaq GlobeNewswire

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

31 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

13 Feb 2025 05:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

06 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

04 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

27 Jan 2025 05:30:00 By Nasdaq GlobeNewswire

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

31 Dec 2024 07:30:17 By Nasdaq GlobeNewswire

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

26 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

05 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

21 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

16 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Veru to Present at the 2024 Cantor Global Healthcare Conference

11 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

08 Aug 2024 05:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

01 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Veru to Participate in the BTIG Virtual Biotechnology Conference

29 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

02 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

24 Jun 2024 07:30:00 By Nasdaq GlobeNewswire